

**Dr. Konstantinos Mavridis**

**Date and Place of Birth:** 1984, Athens, Greece  
**Citizenship:** Greek  
**Work address:** Institute of Molecular Biology and Biotechnology (IMBB)-FORTH, Nikolaou Plastira 100 GR-70013, Heraklion, Crete GREECE  
 Tel: +30-690-689-6047, +30-2810-394438  
 E-mail: [mavridiskos@gmail.com](mailto:mavridiskos@gmail.com), [konstantinos\\_mavridis@imbb.forth.gr](mailto:konstantinos_mavridis@imbb.forth.gr)

**Web:**   **Scopus\***

**Languages:** Greek and English

**University Education**

PhD in Molecular Diagnostics/Clinical Biochemistry at the Dept. of Biochemistry and Molecular Biology, Faculty of Biology, Univ. of Athens (2008-2013)

BSc, Biology, Univ. of Athens, Athens, Greece (2002-2007)

**Previous Positions**

**2016-present:** Postdoctoral researcher, IMBB-FORTH (Molecular Diagnostics- Vector-borne diseases)

**2015- 2016:** Biologist at 401 General Army Hospital (military service)

**2013-2015:** Postdoctoral research fellow, Faculty of Biology, Univ. of Athens (Molecular Diagnostics- Cancer)

**2008-2013** Research associate, Faculty of Biology, Univ. of Athens

**Research records**

- ✓ **58** publications in international peer-reviewed scientific journals (since 2010) / **1** book chapter.
- ✓ Total impact factor, **I.F. = 283**, **Average IF = 4.9**, **1150 citations**, **h-index=20**, **i10-index=38** (Sept 2021).
- ✓ Co-inventor in **2 Patents: 1.** “Methods for Predicting the Survival Time and Treatment Responsiveness of a Patient Suffering from a Solid Cancer», international application number: PCT/EP2016/067424, reference: 15305207.1, Inserm Transfert SA, Paris, France, 2015. **2.** P534198GB Malaria Biomarkers, Method of identifying mosquitoes with infective Plasmodium sporozoites in their salivary glands, 2018
- ✓ **44** publications in proceedings of international and national scientific conferences (11 oral/33 poster)
- ✓ **Reviewer for 3 Grant Agencies:** (1) Institut Pasteur: Actions Concertées InterPasteuriennes, (2) Grant Agency of Romania (UEFISCDI), (3) Science Fund of the Republic of Serbia.
- ✓ Reviewer for **59 international scientific journals:**  
 Cellular Physiology and Biochemistry, Journal of Medicine, Computational and Structural Translational Medicine, Scientific Reports, Biotechnology, Journal for ImmunoTherapy of Oncotarget, Translational Research: The Journal of Cancer, Epigenomics, Cell Proliferation, Cancer Laboratory and Clinical Medicine, Clinical Gene Therapy, BMC Cancer, Expert Review of Chemistry and Laboratory Medicine, Cancer Molecular Diagnostics, Malaria Journal, PLOS

Neglected Tropical Diseases, PLOS ONE, Journal of Pest Science, Expert Opinion on Therapeutic Targets, Biological Chemistry, European Journal of Clinical Investigation, Annals of Clinical Biochemistry, Cell Biology and Toxicology, Biomedicine & Pharmacotherapy, Pathogens, Ecology and Evolution, Bioscience Reports, Cancer Management and Research, Insects, Briefings in Functional Genomics, FEBS Open Bio, Infectious Diseases of Poverty, Tropical Medicine & International Health, International Journal of Environmental Research and Public Health, International Journal of Oncology, Biomarkers in Medicine, Journal of Gastrointestinal Oncology,

Molecular Biology Reports, World Journal of Gastroenterology, World Journal of Surgical Oncology, Cancer Biomarkers, Cancers Journal of Cancer, Springer Plus, International Journal of Molecular Sciences, Preparative Biochemistry and Biotechnology, Cell Biology International, Disease Markers, International Scholarly Research Notices, Journal of International Medical Research, OncoTargets and Therapy, Brazilian Journal of Medical and Biological Research, Diagnostics, Sustainability, Viruses, Asian Pacific Journal of Tropical Medicine, Marine Drugs, Cancer Investigation, Genetic Testing and Molecular Biomarkers, Biomedicines.

✓ Participation in >10 research grants.

### Awards and Distinctions

- Fellowship from the State Scholarships Foundation (IKY) for post-doctoral research, 2020.
- Top 3 reviewers of the Expert Collection of peer-reviewed journals (Taylor & Francis Group), 2020.
- Top 100 articles in Scientific Reports journal (New rapid one-step PCR diagnostic assay for Plasmodium falciparum infective mosquitoes), 2018.
- Fellowship for participation upon selection in the 14<sup>th</sup> FEBS Young Scientists' Forum (YSF), Paris, France, 2014.
- First prize for oral presentation during the “18<sup>th</sup> Panhellenic Congress of Clinical Oncology”, Athens, Greece, 2012.
- E.K.Frey - E.Werle Young Investigator Award 2011.
- Fellowship for participation upon selection in the 61<sup>st</sup> Lindau Nobel Laureate Meeting dedicated to Physiology/Medicine, June 2011
- First prize for poster presentation: “8<sup>th</sup> Tumor markers-targeted Therapy Congress”, Athens, Greece, November 2010.
- Fellowships for participation in Federation of the Societies of Biochemistry and Molecular Biology (FEBS): FEBS Advanced Lecture Course, Matrix Pathobiology, Signaling and Molecular Targets, Patras, Greece, July 2009 and 33<sup>th</sup> FEBS Congress & 11<sup>th</sup> IUBMB Conference, Athens, July, 2008.

- Fellowship from the State Scholarships Foundation for excellent performance during university exams (2004).

### Teaching experience

-Teaching in undergraduate and postgraduate courses of the Medical School of the University of Crete (Molecular diagnostics of cancer) (2019- today).

-Teaching in postgraduate courses of the Pulmonary Medicine Department, University Hospital of Heraklion (2019- today).

-Teaching in postgraduate courses of the University of West Attica (Molecular epidemiology of cancer) (2019-today)

-Teaching in the postgraduate courses "Biostatistics-Bioinformatics" in the Postgraduate program of Clinical Biochemistry - Molecular Diagnostics (2012-2015).

-Assistance in the teaching and supervision of laboratory practicals, for the courses of Basic Biochemistry I, Basic Biochemistry II, Clinical Chemistry of undergraduate students of Biology and Pharmacy (2007-2015)

-Assistant supervisor of 6 "4<sup>th</sup> year projects" and 4 Master theses in the Department of Biochemistry and Molecular Biology, University of Athens (2008-2015).

### Laboratory skills

Droplet Digital PCR (ddPCR), Real-time PCR, High resolution melting curve analysis, RT-PCR, PCR-RFLP, Allele-specific PCR, ARMS PCR, PCR multiplexing, Sanger Sequencing, Next-Generation Sequencing on the Ion Torrent platform, Sanger Sequencing, MLPA, Methylation status analysis, Ligase chain reaction (LCR), Loop-mediated isothermal amplification (LAMP), DNA- RNA- and

protein extraction from cells and human tissues, serum (including ctDNA and miRNA extraction), and urine, FFPE tissue preparation, Western Blotting, ELISA, Immunohistochemistry, Cell culturing, Cell proliferation/cell viability assays, RNAi gene silencing, Agarose/polyacrylamide gel Electrophoresis, Light microscopy, Medium preparation, Optical instrumentation.

### Biostatistic and Bioinformatic skills

*Bioinformatics/Gene expression analysis tools:* NCBI Blast, Primer Premier, GeNorm, Normfinder, ABI7500 SDS Software, Stratagene MxPro qPCR software. PCR primer and probe design and customization for a wide variety of assays.

*Database/Statistics:* SPSS, MedCalc, X-tile, GraphPad, StatsDirect, MS Access.

*Meta-analysis:* Oncomine, TCGA database, PrognoScan, Kaplan-Meier Plotter, ProgGene/ProgMir, starBase.

### Computer skills

*Presentation:* MS PowerPoint

*Spreadsheet:* MS Excel

*Word Processing:* MS Word, Apache OpenOffice.

*Operating Systems:* MS Windows XP, 7, 8, 10, Linux

*Web Page Design:* HTML, PHP, MS FrontPage, Macromedia Dreamweaver.

*Other:* Extensive experience in troubleshooting hardware/software problems, installing/managing local networks, PCs and peripherals.

### Other skills

Experience in writing, submitting and managing large scale research grants.

Experience in writing research- review- and editorial- articles.

Experience in laboratory management.

### Current Research Interests

- Development of novel “ready-to-use” molecular diagnostic platforms for monitoring malaria and other disease vector populations.
- Development and application of ddPCR methodologies for disease vector monitoring.
- Insecticide resistance in disease vectors and agricultural pests.
- Biostatistical analyses/Meta-analyses. Validation procedures for biomarker discovery.
- Expression profiling and prognostic significance of miRNAs in human malignancies.
- Liquid Biopsy (ctDNA, exosomes).

### Work Experience

- Research Assistant in 8 national and international research grants (2008-today).
- Project Manager in four EU H2020 projects (2016-today).
- Visiting Scientist, *Albert-Ludwigs-Universität Freiburg (ALU-FR), Hahn-Schickard Research, Germany* (2019)
- Visiting Scientist, Technische Universität München (TUM - TU München), Clinical Research Unit, Department of Obstetrics and Gynecology (2013).
- Teaching in the postgraduate courses "Biostatistics-Bioinformatics" in the postgraduate program of Clinical Biochemistry - Molecular Diagnostics (Academic years: 2012-2015).
- Assistant supervisor of 6 "4<sup>th</sup> year projects" and 4 Master theses in the Department of Biochemistry and Molecular Biology, University of Athens (2008-2015).
- Assistance in the supervision of laboratory practicals, for the courses of Clinical Chemistry and Basic Biochemistry, of undergraduate students of Biology (2007-2015).

### Organization skills

- Project Manager in 3 European H2020 projects (2016-today)

-DMC-MALVEC: <https://dmc-malvec.eu>

-SUPERPESTS: <https://superpests.eu>

-CypTox: <https://cyptox.eu>

- Organization of two laboratory workshops for Molecular Diagnostics (Zambia-2019, Cameroon-2020).
- Member of the Organizing Committee of the 4<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011).
- Member of the Organizing Committee of the International Conference: Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
- Chairperson in the section *Basic Oncology* (oral presentations) at the 8th BUON (Balkan Union of Oncology) Congress, Sibiu, Romania, September 2010.
- Chairperson in the International Conference: Tumour biomarkers: From discovery to clinical applications, Session 7-Novel approaches for urologic tumor biomarker discovery, Anavyssos, Greece, 2014.

#### **Participation in research grants (selected entries)**

- Project title: Automated diagnostic platform, data management system and innovative communication tool, for improving the impact of malaria vector control interventions. DMC-MALVEC (Diagnosis Management Communication - Malaria Vector Control) (2016-)  
Position: Research associate/Project Manager  
Source of funding: EU, H2020 program
- Project title: INFRAVEC2 (2017-)  
Position: Research associate/Project Manager  
Source of funding: EU, H2020 program
- Project title: SuperPersts: Innovations in plant protection (2018-)  
Position: Research associate/Project Manager  
Source of funding: EU, H2020 program
- Project title: "Identification and Evaluation of Novel BIOMarkers for Early Diagnosis, PROgnosis, and Treatment MONitoring of Breast and Prostate Cancers, through the Development of Hypersensitive Molecular Methodologies (BIOPROMO)" (2012-2015)  
Position: Research associate/ Source of funding: European Social Fund and Greek Ministry of Education
- Project title: "Expression analysis and study of a novel molecular biomarker for the diagnosis, prognosis and prediction of treatment outcome of prostate cancer patients" (2009-2011).  
Position: Research assistant/ Source of Funding: Ministry of Health and Social Solidarity of Greece, Athens, Greece.
- Project title: "Prostate cancer biomarkers" (Greece-Czech cooperation, 2008).

Position: Research assistant/ Source of Funding: General Secretary for Research and Technology of Greece, Athens, Greece

- Project title: “Study and expression analysis of apoptosis-related genes in human osteoarthritis”

Position: Research assistant/ Source of Funding: 1<sup>st</sup> Orthopaedic Clinic of the University of Athens, Athens, Greece.

- Project title: “Expression analysis of L-DOPA decarboxylase levels in cancer cells. Study of its differential diagnostic and prognostic value in prostate cancer”

Position: Research assistant/ Source of Funding: European Social Fund and Greek Ministry of Education (EPEAEK II), Athens, Greece.

## APPENDIX: List of publications

## List of publications in international peer-reviewed scientific journals and books

*\*corresponding author*

(\* = corresponding author)

1. Vlogiannitis S, **Mavridis K**, Dermauw W, Snoeck S, Katsavou E, Morou E, Harizanis P, Swevers L, Hemingway J, Feyereisen R, Van Leeuwen T, Vontas J (2021). Reduced pro-insecticide activation by cytochrome P450 confers coumaphos resistance in the major bee parasite *Varroa destructor*. *PNAS*; 118(6):e2020380118. (IF = 11.205).
2. **Mavridis K\***, Michaelidou K, Vontas J. (2021) Highly sensitive droplet digital PCR-based diagnostics for the surveillance of malaria vector populations in low transmission and incipient resistance settings. *Exp Rev Mol Diagn.* 9;1-10. Online ahead of print. (IF = 5.225).
3. **Mavridis K\***, Papapostolou KM, Riga M, Ilias A, Michaelidou K, Bass C, Van Leeuwen T, Tsagkarakou A, Vontas. Multiple TaqMan qPCR and droplet digital PCR (ddPCR) diagnostics for pesticide resistance monitoring and management, in the major agricultural pest *Tetranychus urticae*. *Pest Manag Sci*; doi: 10.1002/ps.6632. Epub ahead of print. (IF = 4.845).
4. Sene NM, **Mavridis K** (equal first), Ndiaye E, Diagne CT, Gaye A, Ngom EM, Ba Y, Diallo D, Vontas J, Dia I and Diallo M. (2021). Insecticide resistance status and mechanisms in *Aedes aegypti* populations from Senegal. *Plos Neglected Tropical Diseases.* 15(5):e0009393 (IF = 4.411).
5. Djiappi-Tchamen B, Nana-Ndjangwo MS, **Mavridis K**, Talipouo A, Nchoutpouen E, Makoudjou I, Bamou R, Mayi AMP, Awono-Ambene P, Tchuinkam T, Vontas J, Antonio-Nkondjio C (2021). Analyses of Insecticide Resistance Genes in *Aedes aegypti* and *Aedes albopictus* Mosquito Populations from Cameroon. *Genes* 2021 May 28;12(6):828. (IF = 4.096).
6. Piameu M, Nwane P, Toussile W, **Mavridis K**, Wipf NC, Kouadio PF, Mbakop LR, Mandeng S, Ekoko WE, Toto JC, Ngaffo KL, Ngo Etounde PK, Ngantchou AT, Chouaibou M, Müller P, Awono-Ambene P, Vontas J, Etang J. Pyrethroid and Etofenprox Resistance in *Anopheles gambiae* and *Anopheles coluzzii* from Vegetable Farms in Yaoundé, Cameroon: Dynamics, Intensity and Molecular Basis. *Molecules.* 2021; 26(18):5543.
7. Talipouo A, **Mavridis K**, Nchoutpouen E, Tchamen B, Fotakis EA, Kopya E, Bamou R, Kekeunou S, Awono-Ambene P, Balabanidou V, Wondji C.S., Vontas J and Antonio-Nkondjio C. (2021) High insecticide resistance mediated by different mechanisms in *Culex quinquefasciatus* populations from the city of Yaoundé, Cameroon. *Scientific Reports*; 11:7322 (IF = 4.379).
8. Michaelidou K, Koutoulaki C, **Mavridis K**, Vorgias E, Papadaki M, Koutsopoulos A, Mavroudis D and Agelaki S. Detection of KRAS G12/G13 mutations in cell free-DNA by Droplet Digital PCR, offers prognostic information for patients with advanced non-small cell lung cancer. (2020) *Cells*; 9(11):2514 (IF = 6.60).
9. Hin S., Baumgartner D, Specht M, Lüddecke J, Arjmand EM, Benita Johannsen B, Schiedel L, Rombach M, Paust N, von Stetten F, Zengerle R, **Mavridis K**, Vontas J, Mitsakakis K. VectorDisk: a Microfluidic Platform Integrating Bioassays for Vector Management and Control (2020). *Processes*; 8(12), 1677 (IF = 2.847).
10. Panoutsopoulou K., Avgeris M., Magkou P., **Mavridis K.**, Dreyer T., Dorn J., Obermayr E., Reinhaller A., Michaelidou K., Mahner S., Vergote I., Vanderstichele A., Braicu I., Sehoul J., Zeillinger R., Magdolen V.,

- Scorilas A. (2020). miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients. *International Journal of Cancer*; 147(12):3560-3573 (IF = 7.396).
11. Silva R., **Mavridis K.**, Vontas J., Rodrigues A., Osório H. (2020). Monitoring and molecular profiling of contemporary insecticide resistance status of malaria vectors in Guinea-Bissau. *Acta Trop*; 206:105440 (IF = 3.112).
  12. **Mavridis K\***, Wipf N, Medves S., Erquiaga I., Müller P, Vontas J. (2019) Rapid multiplex gene expression assays for monitoring metabolic resistance in the major malaria vector *Anopheles gambiae*. *Parasit Vectors*. 6;12(1):9 (IF = 3.876).
  13. Panoutsopoulou K., Avgeris M., **Mavridis K.**, Dreyer T., Dorn J., Obermayr E., Reinthaller A., Michaelidou K., Mahner S., Vergote I., Vanderstichele A., Braicu I., Sehoul J., Zeillinger R., Magdolen V., Scorilas A. (2019) miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. *Carcinogenesis*; 17;41(4):442-451. (IF= 4.944).
  14. Bamou R., Nadege SC., **Mavridis K.**, Tchuinkam T., Wondji C., Vontas J., Antonio-Nkondjio C. (2019) Status of insecticide resistance and its mechanisms in *An. gambiae* from forest settings in South Cameroon. *Genes*. 10(10): 741. (IF = 4.096).
  15. Fotakis EA, Giantsis IA, Castells Sierra J, Tanti D, Balaska S, **Mavridis K.** Kourtidis S, Vontas J, Chaskopoulou A. Population dynamics, pathogen detection and insecticide resistance of mosquito and sand fly in refugee camps, Greece (2020). *Infectious Diseases of Poverty* 9, 30 IF = 4.520).
  16. **Mavridis K\***, Wipf N, Müller P, Traoré MM, Muller G, Vontas J. (2018) Detection and Monitoring of Insecticide Resistance Mutations in *Anopheles gambiae*: Individual vs Pooled Specimens. *Genes*. Oct 3;9(10). pii: E479 (IF = 4.096).
  17. **Mavridis K\***, Fotakis EA, Kioulos I, Mpellou S, Konstantas S, Varela E, Gewehr S, Diamantopoulos V, Vontas J. (2018) Detection of West Nile Virus - Lineage 2 in *Culex pipiens* mosquitoes, associated with disease outbreak in Greece, 2017. *Acta Trop*. 21; 182:64-68 (IF = 3.112).
  18. Kefi M, **Mavridis K.** Simões ML, Dimopoulos G, Siden-Kiamos I, Vontas J. (2018) New rapid one-step PCR diagnostic assay for *Plasmodium falciparum* infective mosquitoes. *Sci Rep*. 23;8(1):1462 (IF =4.379).
  19. Haritos C, Michaelidou K, **Mavridis K.** Missitzis I, Ardavanis A, Griniatsos J, Scorilas A. (2018). Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients. *Clin Exp Med*. 18(2):203-213 (IF = 3.984).
  20. Kyriakou IK, **Mavridis K.**, Kalogianni DP, Christopoulos TK, Ioannou PC, Scorilas A. (2018) Multianalyte Quantitative Competitive PCR for Prostate Cancer Related Gene-Panel based on Optically Encoded Microspheres. *Anal Bioanal Chem*;410(3):971-980 (IF = 4.142).
  21. Kladi-Skandali A, **Mavridis K.** Scorilas A, Sideris DC. (2018). Expressional profiling and clinical relevance of RNase  $\kappa$  in prostate cancer: a novel indicator of favorable progression-free survival. *J Cancer Res Clin Oncol* ;144(10):2049-2057 (IF = 4.553).
  22. Voudouris Ch., **Mavridis K.**, Kalaitzaki A., Skouras P.J., Kati A.N., Eliopoulos P.A., Vontas J., Margaritopoulos J.T. (2017) Susceptibility data for deltamethrin and spinosad for *Ceratitis capitata* populations from Greece. *J Pest Sci* 91(2): 861-871 (IF = 5.918).
  23. Grigoraki L., Puggioli A., **Mavridis K.**, Douris V., Montanari M., Bellini R., Vontas J. (2017) Striking diflubenzuron resistance in *Culex pipiens*, the prime vector of West Nile Virus. *Sci Rep*, 15;7(1):11699, 2017 (IF= 4.379).



24. Kapodistrias N, **Mavridis K**, Batistatou A, Gogou P, Karavasilis V, Sainis I, Briasoulis E, Scorilas A. (2017). Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis. *Oncotarget* ;8(4):6896-6913 (IF= 5.168).
25. Roditakis E, **Mavridis K**, Riga M, Vasakis E, Morou E, Luc Rison J, Vontas J. (2017) Identification and detection of indoxacarb resistance mutations in the para sodium channel of the tomato leafminer, *Tuta absoluta*. *Pest Manag Sci* ;73(8):1679-1688 (IF = 4.845).
26. Guillon A, Gueugnon F, **Mavridis K**, Dalloneau E., Jouan Y., Diot P., Heuzé-Voure'h N., Courty Y., Si-Tahar M. (2016). Interleukin 22 receptor is overexpressed in non-small cell lung cancer and portends a poor prognosis. *Eur Respir J*; 47(4):1277-80. (IF= 16.671).
27. Dalloneau E, Baroukh N, **Mavridis K**, Maillet A, Gueugnon F, Courty Y, Petit A, Kryza T, Del Rio M, Guyetant S, Cadena-Castadena D, Dhommée C, Arnoult C, Scorilas A, Gouilleux-Gruart V. (2016). Downregulation of the neonatal Fc Receptor expression in non-small-cell lung cancer tissue is associated with a poor prognosis. *Oncotarget* ;7(34):54415-54429 (IF= 5.168).
28. Alexandratos A, Moulos P, Nellas I, **Mavridis K**, Dedos SG. (2016). Reassessing ecdysteroidogenic cells from the cell membrane receptors' perspective. *Sci Rep*; 6:20229, (IF= 4.379).
29. **Mavridis K**, Gueugnon F, Petit-Courty A, Courty Y, Barascu A, Guyetant S, Scorilas A. (2015). The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients. *Br J Cancer*; 112(9):1527-35 (IF= 7.640).
30. Avgeris M, **Mavridis K**, Tokas T, Stravodimos K, Fragoulis EG, Scorilas A. (2015). Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment *Carcinogenesis*; 36(5):528-37 (I.F= 4.944).
31. Gueugnon F, Barascu A, **Mavridis K**, Petit-Courty A, Marchand-Adam S, Gissot V, Scorilas A, Guyetant S, Courty Y. (2015). Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer. *Tumor Biol*; 36(7):4979-86 (IF= 3.650).
32. Karaliotas GI, **Mavridis K**, Scorilas A, Babis GC. (2015). Quantitative analysis of the mRNA expression levels of BCL2 and BAX genes in human osteoarthritis and normal articular cartilage: An investigation into their differential expression. *Mol Med Rep*; 12(3):4514-21 (I.F= 2.952).
33. **Mavridis K**, Stravodimos K, Scorilas A. (2013). Down-regulation and prognostic significance of microRNA 224 (miR-224) expression in prostate cancer. *Clin Chem*, 59(1):261-9 (IF= 8.327).
34. **Mavridis K**, Stravodimos K, Scorilas A. (2013). Quantified KLK15 Gene Expression Levels Discriminate Prostate Cancer from Benign Tumors and Constitute a Novel Independent Predictor of Disease Progression. *Prostate* ; 73(11):1191-201 (I.F= 4.104).
35. Florou D, **Mavridis K**, Scorilas A. (2012). The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. *Tumor Biol*, 33(6):2069-78 (IF=3.650).
36. Koutalellis G, Stravodimos K, Avgeris M, **Mavridis K**, Scorilas A, Lazaris A, Constantinides C (2012). L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer. *BJU Int*, 110(6 Pt B):267-73 (IF= 5.588).

37. Xinopoulos D, Bassioukas SP, Kypreos D, Korkolis D, Scorilas A, **Mavridis K**, Dimitroulopoulos D, Paraskevas E. (2011). Pancreatic duct guidewire placement for biliary cannulation in a single-session therapeutic ERCP. *World J Gastroenterol*, 17(15):1989-95 (IF= 5.742).
38. **Mavridis K**, Avgeris M., Koutalellis G, Stravodimos K, Scorilas A. (2010). Expression analysis and study of the *KLK15* mRNA splice variants in prostate cancer and benign prostatic hyperplasia *Cancer Sci*, 101(3):693 – 699 (IF= 6.716)
39. **Mavridis K**, Talieri M, Scorilas A. (2010). *KLK5* gene expression is severely upregulated in androgen independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. *Biol Chem*, 391(4):467-74., 2010 (IF= 3.915).
40. Konstantoudakis G, Florou D, **Mavridis K**, Papadopoulos IN, Scorilas A. (2010). Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. *Clin Biochem*, 43(15):1205-11 (I.F= 3.281).
41. Xinopoulos D, Kypreos D, Bassioukas SP, Korkolis D, **Mavridis K**, Scorilas A, Dimitroulopoulos D, Loukou A, Paraskevas E. (2010). Comparative study of balloon and metal olive dilators for endoscopic management of benign anastomotic rectal strictures: clinical and cost-effectiveness outcomes. *Surg Endosc*, 25(3):756-63 (I.F= 4.584).
42. Thomadaki H, **Mavridis K**, Talieri M, Scorilas A. (2009) Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. *Thromb Haem*. 101(2):373-80 (I.F= 5.249).

### **B. Reviews**

43. Michaelidou K, Agelaki S., **Mavridis K\*** (2020). Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises *Expert Rev Mol Diagn*;20(3):335-344 (IF=5.225).
44. Van Leeuwen T., Dermauw W., **Mavridis K**, Vontas J. (2020) Significance and interpretation of molecular diagnostics for insecticide resistance management of agricultural pests. *Current Opinion in Insect Science*, 39:69-76. (IF = 5.186).
45. Vontas J., Katsavou E., **Mavridis K**. (2020). Cytochrome P450-based metabolic insecticide resistance in *Anopheles* and *Aedes* mosquito vectors: muddying the waters. *Pestic Biochem Physiol.*;170:104666 (IF= 3.963).
46. Vontas J. **Mavridis K**. (2019). Vector population monitoring tools for insecticide resistance management: myth or fact? *Pestic Biochem Physiol.* ;161:54-60 (IF= 3.963).
47. Mitsakakis K, Hin S, Müller P, Wipf N, Thomsen E, Coleman M, Zengerle R, Vontas J, **Mavridis K**. (2018). Converging Human and Malaria Vector Diagnostics with Data Management towards an Integrated Holistic One Health Approach. *Int J Environ Res Public Health*. 2018 Feb 3;15(2). pii: E259 (IF = 3.390).
48. Kladi-Skandali A, Michaelidou K, Scorilas A, **Mavridis K\***. (2015). Long Noncoding RNAs in Digestive System Malignancies: A Novel Class of Cancer Biomarkers and Therapeutic Targets? *Gastroenterol Res Pract.*; 2015:319861 (IF= 2.260).
49. Scorilas A, **Mavridis K**. (2014). Predictions for the future of kallikrein-related peptidases in molecular diagnostics. *Expert Rev Mol Diagn.* ;14(6):713-22 (IF=5.225).

50. **Mavridis K**, Avgeris M, Scorilas A. (2014) Targeting kallikrein-related peptidases in prostate cancer. *Expert Opin Ther Tar*; Apr;18(4):365-83 (I.F= 6.902).
51. Kontos CK, **Mavridis K**, Talieri M, Scorilas A. (2013) Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: Mechanistic and clinical aspects. *Thromb Haem*; 109(5) (I.F=5.249).
52. Avgeris M, **Mavridis K**, Scorilas A. (2012). Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. *Biol Chem*, 393(5):301-17 (IF=3.915).
53. Avgeris M, **Mavridis K**, Scorilas A. (2010). Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. *Biol Chem*, 391(5):505-11 (IF=3.915)
54. **Mavridis K** and Scorilas A. (2010) Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. *Future Oncol*, 6(2):269-85 (IF= 3.404).

### C. Editorials

55. **Mavridis K\***. and Michaelidou K. (2019). The obesity paradox in lung cancer: Is there a missing biological link? *Journal of Thoracic Disease, J Thorac Dis*. 11(3): S363-S366 (IF = 2.895).
56. **Mavridis K\***. (2017). Long Non-Coding RNAs In Gastric Cancer: A True Relationship or miR Chance? *Dig Dis Sci*. ;62(11):2952-2954 ) (IF = 3.199).
57. Scorilas A, **Mavridis K**, Magdolen V, Fritz H. (2012) Highlight: the 4th International Symposium on Kallikreins and Kallikrein-related peptidases. *Biol Chem*, 393(5):299-300 (IF=3.915).
58. Scorilas A, **Mavridis K**. (2012). Kallikrein-related peptidases (KLKs) as novel potential biomarkers in gastric cancer: An open yet challenging road lies ahead. *J Surg Oncol*, 105(3):223-4 (I.F= 3.454).

### D. Book Chapters

**Mavridis K.**, Schmitt M. Scorilas, A. (2012) Chapter 10: Kallikrein-related Peptidases as Biomarkers in Personalized Cancer Medicine *Kallikrein-related peptidases: Novel cancer-related biomarkers*, pp: 201-218. Edited by Magdolen V., Sommerhoff C.P., Fritz H., Schmitt M., *DE GRUYTER* Publishing Group.

### List of publications in conference proceedings (selected entries)

1. **Mavridis K**, Wipf N., Medves S., Müller P., Vontas J. Multiplex Molecular Diagnostic Assays for Improving the Impact of Vector Control Interventions. Ento '19 RES International Symposium & National Science Meeting. London, UK. August 2019.
2. Vlogiannitis S., **Mavridis K.**, Dermauw W3., Snoeck S., Katsavou E., Morou E., Harizanis P., Swevers L., Van Leeuwen T, Vontas J Biochemical and molecular characterization of a striking coumaphos resistance mechanism in *Varroa destructor*. 46<sup>th</sup> Apimondia International Apicultural Congress Montréal, 8-12 September 2019.
3. **Mavridis K**, Vontas J. Automated "sample to answer" diagnostic platforms (MalVecLabDisk / ArboVec-Disk) for improving the impact of vector control interventions. Molecular Diagnostics Europe, Lisbon, Portugal, May 2018.
4. **Mavridis K**, Vontas J. Evidence based IRM: the value of molecular diagnostics and bioassays. American Society of Tropical Medicine Hygiene Annual Meeting, Baltimore, US, November 2017.
5. **Mavridis K.**, Gueugnon F., Petit-Courty A., Courty Y., and Scorilas A. CEACAM19, the latest member of the CEACAM family of cancer-related cell adhesion molecules, represents a novel biomarker for lung cancer prognosis. FEBS-EMBO 2014, Paris, France, 2014.

6. Kladi-Skandali A, **Mavridis K**, Kontos CK, Sideris DC and Scorilas A. Investigation of the effect of chemotherapeutic drugs on the multiple mol diangression levels of the KLKs, DDC, RNASEK and BCL2L12 genes in human breast and prostate cancer cells. New promising indicators for predicting chemotherapy response, Cancer Therapy, November 03-05, Valencia, Spain, 2015.
7. Kyriakou I, **Mavridis K**, Kalogianni DP., Ioannou PC., Christopoulos TK., Scorilas A. Multianalyte assay for prostate cancer-related gene quantification by hybridization on fluorescent microspheres 9<sup>th</sup> International Conference on "Instrumental Methods of Analysis-Modern Trends and Applications, Greece, September, 2015.
8. **Mavridis K**, Michaelidou K., Welk A., Schmitt M., Scorilas A. Identification of miRNAs as novel biomarkers in the decision-making process for ovarian cancer management. *Proc. International Conference Tumour biomarkers: From discovery to clinical applications*, Anavyssos, Greece, 2014.
9. Michaelidou K, **Mavridis K**, Kladi-Skandali A., Ardavanis A., Scorilas A. mRNA expression analysis of the tumor-related genes KLK6, KLK8 and KLK11 reveals their potential as prognostic biomarkers for breast cancer. *Proc. International Conference Tumour biomarkers: From discovery to clinical applications*, Anavyssos, Greece, 2014.
10. **Mavridis K**, Stravodimos K., Scorilas A. microRNA 224: A KLK-Targeting miRNA with Deregulated Expression and Promising Prognostic Value in Prostate Cancer. *Proc. 5<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013)*, pp46, Toronto, Canada, 2013.
11. Michaelidou K, Mavridis K., Haritos C., Ardavanis A., Scorilas A. KLK8 mRNA expression analysis in breast cancer: evaluation of its clinical significance. *Proc. International Society of Enzymology Meeting (ISE)*, Kos, Greece, 2014.
12. Avgeris M, **Mavridis K**, Stravodimos K., Scorilas A. Downregulation of the KLK2- and KLK4- targeting miR-378a predicts short term relapse of prostate cancer patients. *Proc. 5<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013)*, pp50, Toronto, Canada, 2013.
13. Dedos S. G., Nellas I. and **Mavridis K**. Profiling of signalling receptome in prothoracic gland cells of *Bombyx mori*. *Proc. 9<sup>th</sup> International Workshop on Molecular Biology and Genetics of the Lepidoptera*. Crete, Greece, 2014.
14. **Mavridis K**, Stravodimos K., Scorilas A. The miR-224-KLK15 axis in prostate tumors: Deregulation and prognostic significance. *Proc. 64<sup>th</sup> Congress of the Hellenic Society of Biochemistry and Molecular Biology*, pp17, Athens, Greece, 2013.
15. **Mavridis K**, Stravodimos K., Scorilas A. Quantitative analysis and evaluation of KLK15 classical mRNA transcript levels as a biomarker of disease progression in prostate cancer. *Proc Advances in Circulating Tumour Cells (ACTC 2012)*, P32, pp110, Athens, September 2012.
16. **Mavridis K**, Avgeris M., Stravodimos K. and Scorilas A. Expression analysis of miR-145 and miR-224 in prostate cancer: differential diagnostic and prognostic significance. *P28-10, P28-9 Proc FEBS 2012, Seville, Spain, 2012 & FEBS Journal 279 (Suppl. 1) 600-608, pp 602-603, 2012.*
17. Kontos C.K., **Mavridis K** and Scorilas A. Quantitative Expression Analysis And Study Of BCL2L12 And Other Members Of The BCL2 Apoptosis-Related Gene Family, As Promising Biomarkers For Monitoring Of Prostate And Colon Cancer Cellular Response To Chemotherapy. *Proc 22<sup>nd</sup> ETRS meeting*, pp 72, 4-5 October 2012, Athens, Greece, 2012.

18. Kontos C.K., Thomadaki H., **Mavridis K.**, Ardavanis A., and Scorilas A. Identification and molecular cloning of novel splicing variants of BCL2L12, a new member of the BCL2 family, and their expression analysis in breast, prostate, and colon cancer cells. *Proc. of the 103<sup>rd</sup> Annual Meeting of the American Association for Cancer Research*; Cancer Res 2012; 72(8 Suppl): Abstract nr 2006, Chicago, IL. Philadelphia (PA): AACR; Mar 31-Apr 4, 2012.
19. Michaelidou K., Tzouvaras A., Tsoukalas N., **Mavridis K.**, Tsoukalas G., Tsapralis N., Stamatopoulou S., Zylis D., Misitzis I., Ardavanis A. and Scorilas A. Evaluation of the Clinical Utility of Kallikrein-Related Peptidase 6 Gene (KLK6) downregulation in Breast Cancer. American Society of Clinical Oncology (ASCO) Annual Meeting 2012, Chicago, Illinois, June 2012.
20. **Mavridis K.**, Tzouvaras A. Stravodimos K., Stamatopoulou S., Dokou A., Kaltsas S., Ardavanis A and Scorilas A. Expression analysis of *KLK15* and miR-224 in prostate cancer. 18<sup>th</sup> Panhellenic Congress of Clinical Oncology, Athens, Greece, 2012 (*1<sup>st</sup> oral presentation prize*).
21. **Mavridis K.**, Stravodimos K., Scorilas A. Quantitative Analysis And Study Of The microRNA 224 (mir-224) And Its Target, *KLK15* Gene, In Prostate Tumors: Investigation Of Their Clinical Significance *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, OP18, pp.50, September 2011 (*selected oral presentation*).
22. Florou D., **Mavridis K.**, Scorilas A. Exposure Of Gastric Cancer Cells To Various Antineoplastic Drugs Modifies *KLK13* mRNA Expression Levels. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P32, pp.78, September 2011.
23. Karaliotas G. I., **Mavridis K.**, Scorilas A., Babis G. C. Expression Analysis Of The mRNA Levels Of Kallikrein-Related Peptidases In Human Osteoarthritis. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P23, pp.73, September 2011.
24. Tzouvaras A., **Mavridis K.**, Ardavanis A. and Scorilas A. Expression Analysis and Study of BCL2 and the Novel Member of the Apoptotic Genes BCL2L12, as Promising Biomarkers for Monitoring of Prostate Cancer Cells' Response to Chemotherapy. *European Multidisciplinary Cancer Congress, 16th ECCO, 36th ESMO, 30th ESTRO Congress, Stockholm, European Journal Of Cancer Volume: 47 Supplement: 1 pp: S173-S173*, September 2011.
25. Karaliotas G.I., **Mavridis K.**, Scorilas A., Babis G. mRNA expression Analysis Of *BCL2*, *BAX* And *BCL2L12* Apoptotic Genes In Osteoarthritis., *Proc.American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, San Diego, CA, USA, February 2011*, pp226, Poster No. P188, 2011.
26. **Mavridis K.**, Thomadaki H., Ardavanis A., Scorilas A. Treatment of androgen independent prostate cancer cells with methotrexate leads to apparent upregulation of the mRNA levels of Kallikrein genes *KLK5*, *KLK13* and *KLK15*. *Journal of BUON*, Vol.15, Supp1, OP58, pp20, 6 and 8th Congress of the Balkan Union of Oncology, Sibiu, Romania, September 2010. September 2010 (*selected oral presentation*).
27. Tzouvaras A., **Mavridis K.**, Thomadaki H., Doufexis D., Maliou S., Kountourakis P., Malamos N., Ardavanis A., Scorilas A. Molecular analysis and study of BCL2 gene family members of the apoptotic genes as promising biomarkers for monitoring breast, prostate and ovarian cancer cells' response to chemotherapy *Journal of BUON*, Vol.15, Supp1, OP55, pp20 and 6. 8th Congress of the Balkan Union of Oncology, Sibiu, Romania, September 2010 (*selected oral presentation*).

28. **Mavridis K.**, Stravodimos K., Ardavanis A., and Scorilas A. Quantitative analysis of KLK13 expression in prostate cancer and benign prostatic hyperplasia, "8th Tumor markers-targeted Therapy Congress", Athens, Greece, November 2010. (*1<sup>st</sup> poster prize*)
29. **Mavridis K.**, Thomadaki H., Talieri M., Scorilas A. Prostate Cancer Cells Respond to Mitoxantrone and Doxorubicin treatment by modulating the Expression Profiles of *BCL2* Apoptotic Family Genes and the kallikrein-related peptidase 5 (*KLK5*). *Proc International Society for Enzymology, Conference On Enzymes New Roles for Old Molecules*, P16, 2010.
30. Koutalellis G., Stravodimos K., Avgeris M., **Mavridis K.**, Scorilas A., Constandinides C. Clinical and molecular differences between benign prostate hyperplasia and prostate cancer. *Proc. 3rd World Congress on Controversies in Urology (CURy)*, A-25, 2010.
31. Dimitrakopoulou D., **Mavridis K.**, Margaritis A., Stravodimos K. and Scorilas A. Evaluation of the Differential Diagnostic Potential of the mRNA Transcripts Encoded by the Novel Gene *KLK15* in Prostate Tumors. *Proc. 32<sup>nd</sup> Annual Congress of Hellenic Society for Biological Sciences*, pp 95, 2010.
32. Tzouvaras A., **Mavridis K.**, Doufeksis D., Maliou S., Thomadaki H., Kountourakis P., Talieri M., Ardavanis A. and Scorilas A. Expression analysis and study of the role of novel genes as molecular markers for determining prostate, breast and ovarian cancer cells' response to chemotherapy *Proc. 16<sup>th</sup> Annual Hellenic Congress on Clinical Oncology*, 2010.
33. **Mavridis K.**, Scorilas A. Treatment of prostate cancer cells with chemotherapeutic agents induces distinct alterations in the mRNA expression pattern of the kallikrein-related peptidases genes *KLK13* and *KLK15*. *Proc. International Conference on Molecular Cancer Research* O-24, 2009 (*selected oral presentation*).
34. **Mavridis K.**, Talieri M., Scorilas A. Expression profiles of the *KLK5* and *KLK15* genes in the androgen independent prostate cancer cells after treatment with the anticancer agents mitoxantrone, doxorubicin and epirubicin *Proc Int Symp Kallikreins: L9.4*, 2009 (*selected oral presentation*).
35. Florou D, Konstantoudakis G, **Mavridis K.**, Papadopoulos IN, Scorilas A. Quantitative analysis of *KLK13* mRNA expressional status and its clinical value in human primary gastric carcinomas *Proc Int Symp Kallikreins: P12*, 2009.
36. **Mavridis K.**, Koutalellis G, Stravodimos K, Scorilas A., Quantitative analysis of the kallikrein-related peptidase 13 in prostate tumors *Proc Int Symp Kallikreins: P19*, 2009.
37. Micahaelidou K., **Mavridis K.**, Scorilas A. Expression analysis of the kallikrein genes *KLK11* and *KLK13* in cancer cells and prostate tumors. *Proc 31th Annual Congress of Hellenic Society for Biological Sciences*, pp231, 2009.
38. **Mavridis K.**, Scorilas A. Preclinical evaluation of the novel Kallikrein genes *KLK13* and *KLK15* as new putative molecular markers for difeerencial diagnosis and suitable therapeutic handling of prostate cancer. *FEBS JOURNAL*, 69, 143-143, 2009.
39. Thomadaki H, **Mavridis K.** and Scorilas A. BCL-2, BAX and BCL2L12 are modulated at the mRNA level in response of leukemic cells to the ABL protein tyrosine kinase inhibitor, Gleevec *FEBS JOURNAL*, 275: 110-110, 2008.
40. Thomadaki H, **Mavridis K.**, Tsiapalis CM, Gourgiotis D and Scorilas A. Effect of Zn<sup>2+</sup>, a caspase regulator, on survival of U937 cells, a human histolytic lymphoma cell line: implication of polyadenylation. *Proc Int Prot Soc: P 291*, 2007.

41. Avgeris M, **Mavridis K.**, Thomadaki H, Kontos Ch, Avzioti K, Papalexis P, **Scorilas A.** Expression analysis of the genes KLK4 and KLK15 in cancer cell lines. *Proc Int Symp Kallikreins: P43, 2007.*
42. **Mavridis K.**, Avgeris M, Koutalellis G, Stravodimos K, Scorilas A. Clinical evaluation of the KLK15 mRNA spliced variants in prostate tumors. *Proc Int Symp Kallikreins: P44, 2007.*
43. Thomadaki H, **Mavridis K.**, Talieri M, Scorilas A. Kallikreins 11 and 15 are new putative molecular markers for suitable therapeutic handling of prostate cancer. *Proc Int Symp Kallikreins: P46, 2007.*
44. **Mavridis K.**, Avgeris M., Koutalellis G, Stravodimos K, Scorilas A. Expression analysis and study of the novel KLK15 (Kallikrein 15) gene in prostate tumors. *Proc 29th Annual Congress of Hellenic Society for Biological Sciences, pp 75, 2007.*